{"id":960579,"date":"2026-05-11T06:49:21","date_gmt":"2026-05-11T10:49:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-corporation-presents-new-data-from-teton-1-advance-outcomes-and-additional-research-in-pulmonary-hypertension-and-pulmonary-fibrosis-at-ats-2026\/"},"modified":"2026-05-11T06:49:21","modified_gmt":"2026-05-11T10:49:21","slug":"united-therapeutics-corporation-presents-new-data-from-teton-1-advance-outcomes-and-additional-research-in-pulmonary-hypertension-and-pulmonary-fibrosis-at-ats-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-corporation-presents-new-data-from-teton-1-advance-outcomes-and-additional-research-in-pulmonary-hypertension-and-pulmonary-fibrosis-at-ats-2026\/","title":{"rendered":"United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026"},"content":{"rendered":"

<\/p>\n

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026<\/b><\/p>\n

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF<\/b>) include efficacy and safety results from <\/i>TETON-1 and integrated results from <\/i>TETON-1 and <\/i>TETON-2<\/p>\n

Results from the successful <\/i>ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension (PAH<\/b>) will be presented<\/i><\/p>\n

Additional presentations include an interim analysis from the <\/i>TETON-PPF study of inhaled treprostinil in progressive pulmonary fibrosis (PPF<\/b>), preliminary results from the <\/i>PHINDER study of patients with interstitial lung disease (ILD<\/b>) with and without pulmonary hypertension (PH<\/b>), and interim results from the <\/i>ARTISAN study of parenteral treprostinil in PAH<\/i><\/p>\n

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE<\/a>)–
\nUnited Therapeutics Corporation (Nasdaq: UTHR<\/b>), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS<\/b>) International Conference, May 15-20, in Orlando.<\/p>\n

\n\u201cWe are thrilled to share additional positive data from the TETON-1<\/i> study in IPF and the ADVANCE OUTCOMES<\/i> study in PAH, our pivotal studies that achieved unprecedented results in these two life-threatening diseases that have significant unmet needs. The data we are sharing from our research programs in pulmonary hypertension and ILD, including PHINDER<\/i>, ARTISAN<\/i>, and TETON-PPF<\/i>, will also provide important clinical insights that may meaningfully impact how these devastating diseases are managed and help improve outcomes for the people living with them,\u201d said Andrew Nelsen, PharmD, <\/b>Vice President, Global Medical Affairs at United Therapeutics.<\/p>\n

Poster Presentations Include:<\/b><\/p>\n

ARTISAN Interim Analysis: Early Treatment with High-Dose Treprostinil Reduces Mean Pulmonary Artery Pressure and Improves Risk Status in Pulmonary Arterial Hypertension<\/b><\/a>, Oral Session AQ19, Sunday, May 17, 9:27 – 9:39 am<\/p>\n

Patient Insights into Subcutaneous Pump Therapy in Pulmonary Arterial Hypertension<\/b><\/a>, Poster Session A65, Sunday, May 17, 11:30 am – 1:15 pm<\/p>\n

Accuracy of Clinician Suspicion for Pulmonary Hypertension in Interstitial Lung Disease by Care Setting: Interim Comparison from the PHINDER Study<\/b><\/a>,Poster Session B41,Monday, May 18, 11:30 am – 1:15 pm<\/p>\n

Real-world Dosing of Parenteral Treprostinil Post-Sotatercept Launch<\/b><\/a>, Poster Session B67, Monday, May 18, 11:30 am – 1:15 pm<\/p>\n

Real-World Persistence to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension: A Decade in Review<\/b><\/a>, Poster Session B106, Monday, May 18, 2:15 pm – 4:15 pm<\/p>\n

TETON Phase 3 Clinical Trials of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis: Integrated Efficacy and Safety Results for TETON-1 and TETON-2<\/b><\/a>, Mini-Symposium B95, Monday, May 18, 3:51 pm – 4:03 pm<\/p>\n

Clinical Outcomes with Parenteral Induction Therapy in Patients with Methamphetamine-Associated PAH: A Subgroup Analysis of the EXPEDITE Study<\/b><\/a>,Poster Session C65, Tuesday, May 19, 11:30 am – 1:15 pm<\/p>\n

Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study<\/b><\/a>, Poster Session C104, Tuesday, May 19, 2:15 pm – 4:15 pm<\/p>\n

TETON-1 Phase 3 Clinical Trial of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis<\/b><\/a>, Poster Session C103, Tuesday, May 19, 2:15 pm – 4:15 pm<\/p>\n

TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis<\/b><\/a>, Poster Session C103, Tuesday, May 19, 2:15 pm – 4:15 pm<\/p>\n

ADVANCE OUTCOMES: A Phase 3, Double-Blind, Placebo-Controlled Clinical Trial of Ralinepag for the Treatment of Pulmonary Arterial Hypertension<\/b><\/a>, Poster Session D28, Wednesday, May 20, 8:15 am – 10:15 am<\/p>\n

Real-World Comparison of Antifibrotic-Treated and Untreated Patients with Idiopathic Pulmonary Fibrosis in a Commercial and Medicare Advantage Population<\/b><\/a>, Poster Session D22, Wednesday, May 20, 8:15 am – 10:15 am<\/p>\n

Sponsored events include:<\/b><\/p>\n